Short Interest in HLS Therapeutics Inc. (OTCMKTS:HLTRF) Rises By 269.1%

HLS Therapeutics Inc. (OTCMKTS:HLTRF) saw a large increase in short interest in August. As of August 14th, there was short interest totaling 1,646 shares, an increase of 269.1% from the July 30th total of 446 shares. Based on an average trading volume of 2,461 shares, the short-interest ratio is presently 0.7 days.

HLS Therapeutics Price Performance

OTCMKTS HLTRF opened at $2.68 on Thursday. The stock’s fifty day moving average is $2.97 and its two-hundred day moving average is $3.17. HLS Therapeutics has a fifty-two week low of $2.65 and a fifty-two week high of $4.02.

Wall Street Analyst Weigh In

Separately, Raymond James Financial raised shares of HLS Therapeutics from an “outperform” rating to a “strong-buy” rating in a research note on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Strong Buy”.

HLS Therapeutics Company Profile

HLS Therapeutics is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription products for niche therapeutic markets. Headquartered in Mississauga, Ontario, the company builds its portfolio through strategic licensing agreements and in-house development, with an emphasis on therapies that address unmet needs in neurology and rare disorders.

The company’s marketed offering includes treatments for neurological conditions, most notably primary periodic paralysis, for which it commercializes dichlorphenamide (Keveyis) in North America.